

CARBOPLATIN

INDICATION (ICD10) C71, C72

1. Third-line treatment of fit patients with relapsed high grade glioma. PS 0, 1, 2

REGIMEN

Day 1 CARBOPLATIN AUC 6 in 500ml glucose 5% IV infusion over 30 minutes.

Dose calculated by EDTA GFR or calculated (CrCl + 25) x AUC.

Maximum dose when using CrCl 125+25 x AUC

CYCLE FREQUENCY AND NUMBER OF CYCLES

Every 28 days for 3 to 6 cycles

ANTI-EMETICS

Moderate risk day 1

CONCURRENT MEDICATION REQUIRED

| Carboplatin | Anaphylaxis treatment should be prescribed if the patient has had an |
|-------------|--|
| | anaphylactic episode previously. |
| | Dexamethasone 20mg IV bolus |
| | Chlorphenamine 10mg IV bolus |
| | H ₂ antagonist |
| | Carboplatin should be given at a slower rate e.g. 2-4 hours. |

EXTRAVASATION AND TYPE OF LINE / FILTERS

Carboplatin - irritant

Filter not required Peripheral or central line

INVESTIGATIONS

Blood results required before SACT administration

FBC, U&E and LFTs every cycle

Neutrophils x 10⁹/L ≥1.5

Platelets x 10⁹/L ≥100

GFR assessed using EDTA result or calculated creatinine clearance at the Consultant's discretion.

Patients with hydronephrosis or serum creatinine ≥100micromol/L need a serum creatinine checked every cycle.

Baseline weight and every cycle

MAIN TOXICITES AND ADVERSE REACTIONS

| Carboplatin | Ototoxicity – monitor | |
|-------------|-------------------------|--|
| | Neurotoxicity - monitor | |

DOSE MODIFICATIONS

| GFR / calculated CrCl ≤20ml/min or | contraindicated |
|--|-----------------|
| ≤30ml/min with pre-existing severe renal | |
| impairment | |

REFERENCES

| Carboplatin | CNS CAG approval | Page 1 of 1 | Approved: December 2021 | Version |
|-------------|------------------|-------------|-------------------------|---------|
| | | | Review: December 2023 | 5.0 |